Loading data for ANIX — first visit, this takes a few seconds.

Alert

Anixa Biosciences Inc. (ANIX)

NasdaqCM: ANIX · Real-Time Price · USD

3.49

+0.31 (9.75%)

At close: Aug 18, 2026, 8:00 PM

9.75% (1D)

No data available

Bid	2.48
Market Cap	116.7M
Revenue (ttm)	n/a
Net Income (ttm)	-10.03M
Beta	0.52
EPS (ttm)	-0.29
PE Ratio (ttm)	n/a
Forward PE	-11.06
P/B (ttm)	8.03
P/S (ttm)	n/a
Earnings Date	Sep 9, 2026

Ask	4.09
Volume	315,383
Avg. Volume (20D)	227,190
Open	3.18
Previous Close	3.18
Day's Range	3.14 - 3.50
52-Week Range	2.32 - 5.46
Analyst	n/a
Price Target	n/a
Dividends	n/a
Ex-Dividend Date	n/a

About ANIX

Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines that are focused on critical unmet needs in oncology. Its therapeutics programs comprising the development of liraltagene autoleucel, a chimeric endocrine receptor-T cell therapy, a novel form of chimeric antigen receptor-T cell (CAR-T) technology that is focused on treating ovarian cancer. The company also engaged in the development of a vaccine against breast canc...

[Read more]

Industry Biotechnology

Sector Healthcare

IPO Date Oct 7, 1983

Employees 4

Stock Exchange NasdaqCM

Ticker Symbol ANIX

Website https://www.anixa.com

Full Company Profile

Financial Performance

In 2025, Anixa Biosciences's revenue was 0, an increase of undefined% compared to the previous year's 0. Earnings were -10.93M, a decrease of -12.96%.

Financial Statements

Earnings Surprise

Anixa Biosciences has released their quarterly earnings on Jun 10, 2026:

Revenue of $0 misses estimates by $0, with NaN% YoY growth.

EPS of -0.07 exceeds estimates by 0.03, with 22.22% YoY growth.

Next Earnings Release

Anixa Biosciences Inc. is scheduled to release its earnings on Sep 9, 2026, after market closes.
Analysts project revenue of ... Upgrade

News

3 weeks ago · Zacks

Anixa Biosciences (ANIX) Upgraded to Strong Buy: Here's What You Should Know

Anixa Biosciences (ANIX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

3 weeks ago · Zacks

Are Medical Stocks Lagging Allarity Therapeutics, Inc. (ALLR) This Year?

Here is how Allarity Therapeutics, Inc. (ALLR) and ANIXA BIOSCIENCES INC (ANIX) have performed compared to their sector so far this year.

3 weeks ago · Zacks

New Strong Buy Stocks for July 22nd

HTLD, YEXT, ANIX, WVE and LCNB have been added to the Zacks Rank #1 (Strong Buy) List on July 22, 2026.

1 month ago · Pharmaceutical Technology

Anixa Biosciences secures Korean patent for breast cancer vaccine

The patent expands Anixa’s IP portfolio beyond the US and existing international markets.

1 month ago · Zacks

Here's Why You Should Add ANIX Stock to Your Portfolio Now

Anixa advances cancer vaccines and CAR-T therapies, supported by positive early data, a planned phase II study and expanding intellectual property protection.

Page 1 of 2

Anixa Biosciences Inc. (ANIX)